Oxidative stress and cardiovascular complications in diabetes: Isoprostanes as new markers on an old paradigm

Cardiovascular Research

Volumn 47, Issue 3, 2000, Pages 475-488

  Mezzetti, Andrea ^a   Cipollone, Francesco ^a   Cuccurullo, Franco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cholesterol; Coronary disease; Diabetes; Free radicals; Lipid metabolism

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA TOCOPHEROL; CHOLESTEROL; FREE RADICAL; ISOPROSTANE;

ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE MARKER; DRUG EFFECT; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACIDS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIETARY SUPPLEMENTS; DINOPROST; F2-ISOPROSTANES; HUMANS; HYPERGLYCEMIA; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN ISOFORMS; VITAMIN E;

EID: 0034682966     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00118-8     Document Type: Review

References (121)

1. Bierman E.L. George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. Arterioscler. Thromb. 12:1992;647-656.
2. Pyorala K., Laasko M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 3:1987;463-524.
3. Gerick J.E. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr. Rev. 19:1998;491-503.
4. Chisholm D.J., Camphell L.V., Kraegen E.W. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin. Exp. Pharmacol. Physiol. 24:1997;782-784.
5. Muller D.C., Elahi D., Tobin J.D., Andres R. The effect of age on insulin resistance and secretion: a review. Semin. Nephrol. 16:1996;289-298.
6. Dechenes C.J., Verchere C.B., Andrikopoulos S., Kahn S.E. Human aging is associated with parallel reductions in insulin and amylin release. Am. J. Physiol. 275:1998;E785-E791.
7. Pimenta W., Korytkowski M., Mitrakou A., Jenssen T., Yki-Jarvinen H., Evron W., Dailey G., Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. J Am Med Assoc. 273:1995;1855-1861.
8. Humphriss D.B., Stewart M.W., Berrish T.S., Barriocanal L.A., Trajano L.R., Ashworth L.A., Brown M.D., Miller M., Avery P.J., Alberti K.G., Walker M. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia. 40:1997;1185-1190.
9. Hopkins P.N., Hunt S.C., Wu L.L., Williams G.H., Williams R.R. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Curr. Opin. Lipidol. 7:1996;241-253.
10. Gray R.S., Fabsitz R.R., Cowan L.D., Lee E.T., Howard B.V., Savage P.J. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am. J. Epidemiol. 148:1998;869-878.
11. Fontbonne A., Charles M.A., Thibult M., Richard J.L., Claude J.R., Warnet J.M., Rosselin G.E., Eschwege E. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia. 34:1991;356-361.
12. Abraira C., Colwell J., Nuttall F., et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch. Intern. Med. 157:1997;181-188.
13. Malmberg K., Ryden L., Suad E., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. 26:1995;57-65.
14. Prospective Diabetes Study Group U.K. Intensive blood glucose control with suophonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
15. Nathan D.M. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann. Intern. Med. 124:1996;86-89.
16. Moss S.E., Klein R., Klein B.E., Meuer S.M. The association of glycemia and cause-specific mortality in a diabetic population. Arch. Intern. Med. 154:1994;2473-2479.
17. 1C with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 41:1991;202-209.
18. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med. 46:1996;223-234.
19. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 46:(Suppl. 2):1997;S19-S25.
20. Hotta N. New approaches for treatment in diabetes: aldose reduclase inhibitors. Biomed. Pharmacother. 49:1995;232-243.
21. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes. 40:1991;405-412.
22. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
23. Van Dam P.S., Van Asbeck B.S., Erkelens B.W., Marx J.J.M., Gispen W.-H., Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab. Rev. 11:1995;181-192.
24. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
25. Ido Y., Kilo C., Williamson J.R. Cytosolic NADH/NAD*, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia. 40:(Suppl. 2):1997;S115-S117.
26. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 46:(Suppl. 2):1997;S31-S37.
27. Lyons T.J., Jenkins A.J. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev. 5:1997;365-391.
28. Degenhardt T.P., Brinkmann-Frye E., Thorpe S.R., Baynes J.W. Role of carbonyl stress in aging and age-related diseases. O'Brien J., Nursten H.E., Crabbe M.J.C., Ames J.M. The maillard reaction in food and medicine. 1998;3-10 Royal Society of Chemistry, London.
29. Witztum J.L. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes. 46:(Suppl. 2):1997;S112-S114.
30. Lopes-Virella M.F., Mironova M., Virella G. LDL-containing immune complexes and atherosclerosis in diabetes. Diabetes Rev. 5:1997;410-424.
31. Ishii H., Daisuke K., King G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med. 76:1998;21-31.
32. Pfeiffer A., Schatz H. Diabetic microvascular complications and growth factors. Exp. Clin. Endocrinol. Diabetes. 103:1995;7-14.
33. Sharma K., Ziyadeh F.N. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem. Nephrol. 17:1997;80-92.
34. Mezzetti A., Guglielmi M.D., Pierdomenico S.D., Costantini F., Cipollone F., De Cesare D., Bucciarelli T., Ucchino S., Chiarelli F., Cuccurullo F., Romano F. Increased systemic oxidative stress after elective endarterectomy. Arterioscler. Thromb. Vasc. Biol. 19:1999;2659-2665.
35. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
36. Nishigaki I., Hagihara M., Tsunekawa H., Maseki M., Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem. Med. 25:1981;373-378.
37. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes. 44:1995;1054-1058.
38. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368:1995;225-229.
39. Catella-Lawson F., Kapoor S., Praticò D., Braunstein S.N., Caraballo V., FitzGerald G.A. Oxidative stress and diabetes mellitus. J. Invest. Med. 44:1996;223A. Abstract.
40. 2α and platelet activation in diabetes mellitus. Effects of improved metabolic control. Circulation. 99:1999;224-229.
41. Maillard L.C. Action des adices amines sur les sucres: formation des melanoidines par voie methodique. C.R. Hebd. Seances Acad. Sci. 154:1912;66-68.
42. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to the complications of diabetes. J. Clin. Invest. 91:1993;2470-2478.
43. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification: their potential role of autoxidative glycosylation in diabetes. Biochem. J. 245:1987;243-250.
44. Keaney J.F. Jr., Frei B. Antioxidant protection of low-density lipoprotein and its role in the prevention of atherosclerotic vascular disease. Frei B. Natural antioxidants in human health and disease. 1994;303-352 Academic Press, San Diego, CA.
45. Salvemini D., de Nucci G., Sneddon J.M., Vane J.R. Superoxide anions enhance platelet adhesion and aggregation. Br. J. Pharmacol. 97:1989;1145-1150.
46. Islam K.N., Takahashi M., Higashiyama S., Myint T., Uozumi N. Fragmentation of ceruloplasmin following non-enzymatic glycation reaction. J. Biochem. 118:1995;1054-1060.
47. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269:1994;9889-9897. Abstract.
48. 2-isoprostanes in aging kidneys. Am. J. Physiol. 274:1998;R767-R774.
49. Hangaishi M, Taguchi J, Ikari Y, Umezu M, Watanabe T, Miyata T, Kurokawa K, Kimura T, Ohno M. Advanced glycation end products enhanced the aggregation of human platelets in vitro. Circulation 1997;96(suppl I):I-665.
50. Khechai F., Ollivier V., Bridey F., Amar M., Hakim J., de Prost D. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Arterioscler. Thromb. Vasc. Biol. 17:1997;2885-2990.
51. Rajogopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NAPH oxidase activation. J. Clin. Invest. 97:1996;1916-1923.
52. Lund D.D., Faraci F.M., Miller F.J. Jr., Heistad D.D. Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation. 101:2000;1027-1033.
53. Kamata K., Miyata N., Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 97:1989;614-618.
54. Meraji S., Joakody L., Senaratene M.P., Thomson A.B.R., Kappagoda T. Endothelium-dependent relaxation in aorta of BB rat. Diabetes. 36:1987;978-981.
55. Hohman T.C., Beg M.A. Diabetic complications: progress in the development of treatments. Exp. Opin. Invest. Drugs. 3:1994;1041-1049.
56. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., Van Den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
57. 2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia. 37:1994;264-269.
58. 2 in high-glucose medium. Diabetes. 44:1995;520-526.
59. Yoshida K., Hirokawa J., Tagami S., Kawakami Y., Urata Y., Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia. 38:1995;201-210.
60. Low P.A., Tuck R.R., Dyck P.J., Schmelzer J.D., Yao J.K. Prevention of some electrophysiological and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc. Natl. Acad. Sci. USA. 81:1988;6894-6898.
61. Smith W.L. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu. Rev. Physiol. 48:1986;251-262.
62. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312:1985;159-163.
63. Cameron N.E., Cotter M.A. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab. Rev. 10:1993;189-224.
64. Roberts L.J.I.I., Morrow J.D. The generation and actions of isoprostanes. Biochim. Biophys. Acta. 1345:1997;121-135.
65. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:1990;9383-9387.
66. 2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest. 93:1994;998-1004.
67. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
68. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., FitzGerald G.A. The isoprostanes: a perspective. Prostaglandins. 54:1997;823-851.
69. Lawson J.A., Rokach J., FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274:1999;24441-24444.
70. 2-isoprostane) metabolites in human urine and plasma. J. Biol. Chem. 268:1993;4161-4169.
71. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:1995;94-100.
72. 2α by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J. Biol. Chem. 271:1996;8919-8924.
73. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., FitzGerald G.A. Nomenclature of isoprostanes:a proposal. Prostaglandins. 54:1997;853-873.
74. 2 isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
75. 2α. J. Biol. Chem. 270:1995;9800-9808.
76. 2 isoprostane formation. Br. J. Pharmacol. 118:1996;1285-1293.
77. Panara M.R., Greco A., Santini G., Sciulli G., Rotondo M.T., Padovano R., Di Giamberardino M., Cipollone F., Cuccurullo F., Patrono C., Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl) methanesulphonamide (NS-398) and 5-methanesulphon amido-6-(2,4-difluorothiophenyl)1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br. J. Pharmacol. 116:1995;2429-2434.
78. 2 receptors. J. Clin. Invest. 90:1992;136-141.
79. 2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264:1993;C1619-1624.
80. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271:1996;14916-14924.
81. 2α. J. Biol. Chem. 272:1997;27147-27154.
82. Ferro D., Basili S., Praticò D., Iuliano L., FitzGerald G.A., Violi F. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood. 93:1999;2945-2950.
83. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 44:1992;155-163.
84. 2α. J. Pharmacol. Exp. Ther. 281:1997;957-964.
85. Hou X., Gobeil F., Peri K., Speranza G., Marrache A.M., Lachapelle P., Roberts J., Varma D.R., Chemtob S. Augmented vasoconstriction and thromboxane formation by 15-F-2t-isoprostane (8-iso-prostaglandin F-2 alpha) in immature pig periventricular brain microvessels. Stroke. 31:2000;516-524.
86. 2 receptor in vivo. Circulation, in press.
87. 2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem. 28:(273):1998;22442-22452.
88. Davì G., Catalano I., Averna M., Notarbartolo A., Strano A., Ciabattoni G., Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N. Engl. J. Med. 322:1990;1769-1974.
89. Pieper G.M., Jordan M., Dondlinger L.A., Adams M.B., Roza A.M. Peroxidative stress in diabetic blood vessels: reversal by pancreatic islet transplantation. Diabetes. 44:1995;884-889.
90. 2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur. J. Pharmacol. 377:1999;89-92.
91. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 49:2000;27-29.
92. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
93. Witztum J.L. To E or not to E-how do we tell? Circulation. 50:1998;2785-2787.
94. 2α is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;3230-3235.
95. 2 isoprostanes in hypercholesterolemia. Circulation. 98:1998;2822-2828.
96. 2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation. 95:1997;2492-2499.
97. 2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 96:1997;3314-3320.
98. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davì G, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, in press.
99. 2α-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158:1998;1709-1714.
100. Ciabattoni G, Davì G, Collura M, Iapichino L, Pardo F, Ganci A, Romagnoli R, Patrono C. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med, in press.
101. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332:1995;1198-1203.
102. Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
103. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20:1996;707-727.
104. Patrono C., Davì G., Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc. Med. 2:1992;15-20.
105. Palinski W., Witztum J.L. Oxidative stress and diabetes mellitus. Schwartz C.J., Born G.V.R. New horizons in diabetes mellitus and cardiovascular disease. 1996;81-93 Rapid Science Publishers.
106. Chisolm G.M., Irwin K.C., Penn M.S. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes. 4:1992;61-66.
107. Tsai E.C., Hirsch I.B., Brunzell J.D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014.
108. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum I.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
109. 2-isoprostanes during the oxidative modification of low density lipoprotein. Biochem. Biophys. Res. Commun. 200:1994;338-343.
110. 2alpha - I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA. 95:1998;3449-3454.
111. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17:1997;3236-3241.
112. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103:1999;421-427.
113. Praticò D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-depicient mice. Nature Med. 4:1998;1189-1192.
114. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA. 86:1989;7585-7589.
115. Jha P., Flasher M., Lonn E., Farkouch M., Yusuf S. The antioxidant vitamins and cardiovascular disease. Ann. Intern. Med. 123:1995;860-872.
116. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheseman K., Mitchinson M.J., Brown M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
117. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:2000;154-160.
118. 2-isoprostane and thromboxane biosynthesis in healthy sigarette smokers. Circulation, in press.
119. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet. 354:1999;447-455.
120. Morrow J.D., Minton T.A., Mukundan C.R., Campbell M.D., Zackert W.E., Daniel V.C., Bade K.F., Robert L.J.I.I. Free radical-induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 269:1994;4317-4326.
121. Harrison K.A., Murphy R.C. Isoleukotrienes: biologically active free radical products of lipid peroxidation. J. Biol. Chem. 269:1995;17273-17278.